Illinois is currently home to 2644 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212
Recruiting
This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/14/2025
Locations: Uptown Research Institute Site # 121, Chicago, Illinois
Conditions: Schizophrenia
Register for Updates
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
NCT06883123
Recruiting
A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Prairie Eye Center, Springfield, Illinois
Conditions: Open Angle Glaucoma
Register for Updates
Genicular Artery Embolization for Reducing Pain in Medically Refractory Symptomatic Knee Osteoarthritis
NCT06859164
Recruiting
Genicular Artery Embolization for Reducing Pain in Symptomatic Knee Osteoarthritis: A Pilot Randomized Sham-Controlled Study (SHAM-PAIN) is a NIH-NIAMS funded project designed to assess enrollment feasibility and detect any differences between GAE and a similar sham intervention in reducing KOA-related pain at 3 months as measured by the Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscore. Additionally, this study aims to determine the magnitude of difference in pain response betwe... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/14/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Knee Osteoarthritis, Knee Osteoarthritis (Knee OA), Knee Osteoarthritis (OA)
Register for Updates
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
NCT06480552
Recruiting
The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 * Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab * Determine a RP2D of TEV-56278 in combination with pembrolizumab The secondary objectives of this trial are to: * Characterize the serum pharmacokinetics of TEV-56278 * Evaluate the antitumor activity of TEV-56278 * D... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Teva Investigational Site 12016, Chicago, Illinois
Conditions: Advanced Solid Tumors
Register for Updates
Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants
NCT06206564
Recruiting
This is a phase II double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Anal Dysplasia Clinic MidWest, Chicago, Illinois
Conditions: Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN
Register for Updates
Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients
NCT05918575
Recruiting
Around 20% of the obese patients with higher body mass index (BMI) who are taken off the breathing tube and breathing machine (ventilator) end up needing it back to support breathing. The re-application of breathing tube is associated with poor outcomes, including high risk of pneumonia, longer hospital stays, and death. The purpose of this study is to assess if prophylactic use of noninvasive breathing support after removing the breathing tube lowers the chance of needing the breathing tube aga... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Obesity, Morbid, Extubation Failure
Register for Updates
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
NCT05896839
Recruiting
This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started to other places in the body (metastatic) in kidney transplant recipients. Immunotherapy with nivolumab and ipilimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Sirolimus and prednisone ar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Carcinoma in the Skin, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Register for Updates
Clinical Trial of Approaches to Prostate Cancer Surgery
NCT05155501
Recruiting
This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatectomy. The investigators hypothesize that pelvic fascia-sparing radical prostatectomy will have similar cancer control (primary outcome) and sexual function outcomes; and significantly better urinary function, penile shortening/deformity and inguinal hernia risks as compared to radical prostatectomy.
Gender:
MALE
Ages:
Between 40 years and 80 years
Trial Updated:
05/14/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Prostate Cancer
Register for Updates
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
NCT04573023
Recruiting
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Gender:
ALL
Ages:
All
Trial Updated:
05/14/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Mucopolysaccharidosis II
Register for Updates
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
NCT06527404
Recruiting
The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure of pruritus and overall clinical assessment score (US only).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/13/2025
Locations: Endeavor Health Clinical Trials Center, Skokie, Illinois
Conditions: Prurigo Nodularis
Register for Updates
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT05950464
Recruiting
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killing ovarian tumor cells.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Endometrial Low Grade Endometrioid Adenocarcinoma, Ovarian Low Grade Endometrioid Adenocarcinoma
Register for Updates
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763
Recruiting
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/13/2025
Locations: Rush University Medical Center- Site Number : 8400014, Chicago, Illinois
Conditions: Hemophilia A
Register for Updates